Here, we analyzed the SUMOylation-related gene expression status at the RNA level in kidney cancer tissues and built a risk model using three SUMOylation genes, CDH1, CDCA8, and PPARA, to indicate the outcomes based on differentially expressed SUMOylation genes. This evidence concerns the gene CDH1 and kidney cancer.